A Phase I/II Study of Vorinostat in Combination with Isotretinoin in the Treatment of Patients with Advanced Renal Cell Carcinoma

Study Status

Closed to Enrollment

Study Description

This phase I/II trial is studying the side effects and best dose of isotretinoin when given together with vorinostat and to see how well they work in treating patients with advanced kidney cancer.

Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Isotretinoin may cause kidney cancer cells to look more like normal cells, and to grow and spread more slowly. Giving vorinostat together with isotretinoin may kill more tumor cells.

  • Phase I: Patients receive vorinostat and isotretinoin twice daily on days 3-5, 10-12, 17-19, and 24-26. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
  • Phase II: patients receive vorinostat and isotretinoin at the maximum tolerated dose determined in Phase I.

After completion of study treatment, patients are followed for 12 weeks.

Disease Status and/or Stage

Metastatic or Advanced Kidney Cancer


Weill Cornell Medical College, National Cancer Institute

Key Eligibility

  • Men and women age 21 or older
  • Diagnosed with renal cell carcinoma (kidney cancer)
  • Must have received and failed two or more prior regimens including chemotherapy, immunotherapy, biological agents and/or radiation therapy
  • Additional eligibility discussed when you concact the study team

Principal Investigator

David Nanus, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Erica Bersin
Tel: (646) 962-8232
[email protected]

Top of page